BMI1 and liver cancer: Given that BMI1 is a validated functional SALL4 downstream effector in diverse malignancies, including liver cancer (24), we first examined whether Bmi1 expression is elevated in AY-Sall4 liver compared with AY-GFP control livers (Fig. 4).